These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24144478)

  • 1. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
    Kobayashi H; Iwatsuki-Horimoto K; Kiso M; Uraki R; Ichiko Y; Takimoto T; Kawaoka Y
    Vaccine; 2013 Dec; 31(52):6239-46. PubMed ID: 24144478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
    Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.
    Uraki R; Piao Z; Akeda Y; Iwatsuki-Horimoto K; Kiso M; Ozawa M; Oishi K; Kawaoka Y
    J Infect Dis; 2015 Dec; 212(12):1939-48. PubMed ID: 26123562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.
    Zhan X; Slobod KS; Krishnamurthy S; Luque LE; Takimoto T; Jones B; Surman S; Russell CJ; Portner A; Hurwitz JL
    Vaccine; 2008 Jun; 26(27-28):3480-8. PubMed ID: 18499307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
    Mason JN; Elbahesh H; Russell CJ
    J Virol; 2013 May; 87(10):5959-69. PubMed ID: 23514887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
    Skiadopoulos MH; Surman SR; Riggs JM; Orvell C; Collins PL; Murphy BR
    Virology; 2002 May; 297(1):136-52. PubMed ID: 12083844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection.
    Katsura H; Piao Z; Iwatsuki-Horimoto K; Akeda Y; Watanabe S; Horimoto T; Oishi K; Kawaoka Y
    J Virol; 2014 Nov; 88(22):13410-7. PubMed ID: 25210171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
    Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
    Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
    Liu X; Luongo C; Matsuoka Y; Park HS; Santos C; Yang L; Moore IN; Afroz S; Johnson RF; Lafont BAP; Martens C; Best SM; Munster VJ; Hollý J; Yewdell JW; Le Nouën C; Munir S; Buchholz UJ
    Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live bivalent vaccine for parainfluenza and influenza virus infections.
    Maeda Y; Hatta M; Takada A; Watanabe T; Goto H; Neumann G; Kawaoka Y
    J Virol; 2005 Jun; 79(11):6674-9. PubMed ID: 15890905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.
    Karron RA; Thumar B; Schappell E; Surman S; Murphy BR; Collins PL; Schmidt AC
    Vaccine; 2012 Jun; 30(26):3975-81. PubMed ID: 22178099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus.
    Ui H; Yamayoshi S; Uraki R; Kiso M; Oishi K; Murakami S; Mimori S; Kawaoka Y
    Vaccine; 2017 Apr; 35(15):1892-1897. PubMed ID: 28285982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
    Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
    Liu X; Liang B; Liu X; Amaro-Carambot E; Surman S; Kwong PD; Graham BS; Collins PL; Munir S
    PLoS One; 2020; 15(2):e0228572. PubMed ID: 32045432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.
    Pennathur S; Haller AA; MacPhail M; Rizzi T; Kaderi S; Fernandes F; Bicha L; Schickli JH; Tang RS; Chen W; Nguyen N; Mathie S; Mehta H; Coelingh KL
    J Gen Virol; 2003 Dec; 84(Pt 12):3253-3261. PubMed ID: 14645907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A replication-incompetent PB2-knockout influenza A virus vaccine vector.
    Victor ST; Watanabe S; Katsura H; Ozawa M; Kawaoka Y
    J Virol; 2012 Apr; 86(8):4123-8. PubMed ID: 22301144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2017 Dec; 35(51):7139-7146. PubMed ID: 29153777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.